BEZ235 (NVP-BEZ235, Dactolisib)

Catalog No. A10133

BEZ235 (NVP-BEZ235,Dactolisib)是通过与这些酶的ATP结合裂隙结合来抑制PI3K和mTOR激酶活性。
  • Makoto Koyama, .et al. Low-dose trametinib and Bcl-xL antagonist have a specific antitumor effect in KRAS-mutated colorectal cancer cells, Int J Oncol, 2020, Sep 2 PMID: 32901840
  • Tzeng SF, .et al. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer, FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
  • Dominik Schulz, .et al. HNSCC cells resistant to EGFR pathway inhibitors are hypermutated and sensitive to DNA damaging substances, Am J Cancer Res, 2016, 6(9): 1963-1975 PMID: 27725902
Catalog Num A10133
M. Wt 469.6
Formula C30H23N5O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 915019-65-7
Synonyms
SMILES CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
BEZ235 (NVP-BEZ235,Dactolisib)是通过与这些酶的ATP结合裂隙结合来抑制PI3K和mTOR激酶活性。
Targets
Target Value
p110αIC50: 4nM
p110γIC50: 5nM
mTOR(p70S6K)IC50: 6nM
p110δIC50: 7nM
ATRIC50: 21nM
p110βIC50: 75nM
EGFR/ErbB1IC50: >8.5μM
VEGFR1/FLT1IC50: >10μM
FLT3IC50: >10μM
IGF-1RIC50: >10μM
EphB4IC50: >10μM
RETIC50: >10μM
Tie-2IC50: >10μM
c-MetIC50: >10μM
FGFR(K650E)IC50: >10μM
FAKIC50: >10μM
JAK2IC50: >10μM
c-AblIC50: >10μM
c-SrcIC50: >10μM
PKAIC50: >10μM
Akt1/PKBαIC50: >10μM
PDK-1IC50: >10μM
B-Raf(V599E)IC50: >10μM
CDK1IC50: >10μM
In vitro (25°C) DMSO <1 mg/mL
Water Insoluble
Ethanol Warmed: 16 mg/mL (34.07 mM)
In vivo NMP+PEG300 (10+90, v+v) 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 21.29 mL 106.47 mL 212.95 mL
0.5 mM 4.26 mL 21.29 mL 42.59 mL
1 mM 2.13 mL 10.65 mL 21.29 mL
5 mM 0.43 mL 2.13 mL 4.26 mL

*The above data is based on the productmolecular weight 469.6. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.